Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing
The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS prog...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Siberian State Medical University (Tomsk)
2010-08-01
|
Series: | Bûlleten' Sibirskoj Mediciny |
Subjects: | |
Online Access: | https://bulletin.tomsk.ru/jour/article/view/1646 |
id |
doaj-df47fe7c7fc74ac2969997274c25017a |
---|---|
record_format |
Article |
spelling |
doaj-df47fe7c7fc74ac2969997274c25017a2021-07-29T08:37:52ZengSiberian State Medical University (Tomsk)Bûlleten' Sibirskoj Mediciny1682-03631819-36842010-08-019415215510.20538/1682-0363-2010-4-152-1551148Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressingI. V. Smagina0S. A. Yelchaninova1A. V. Popovtseva2Yu. N. Ignatova3A. O. Gridina4A. S. Fedyanin5ГУЗ «Краевая клиническая больница»Алтайский государственный медицинский университетАлтайский государственный медицинский университетГУЗ «Краевая клиническая больница»ГУЗ «Краевая клиническая больница»ГУЗ «Краевая клиническая больница»The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS progressing is associated with the high level of adhesion molecule (sPECAM) in cerebrospinal fluid.https://bulletin.tomsk.ru/jour/article/view/1646multiple sclerosiscerebrospinal fluid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
I. V. Smagina S. A. Yelchaninova A. V. Popovtseva Yu. N. Ignatova A. O. Gridina A. S. Fedyanin |
spellingShingle |
I. V. Smagina S. A. Yelchaninova A. V. Popovtseva Yu. N. Ignatova A. O. Gridina A. S. Fedyanin Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing Bûlleten' Sibirskoj Mediciny multiple sclerosis cerebrospinal fluid |
author_facet |
I. V. Smagina S. A. Yelchaninova A. V. Popovtseva Yu. N. Ignatova A. O. Gridina A. S. Fedyanin |
author_sort |
I. V. Smagina |
title |
Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing |
title_short |
Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing |
title_full |
Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing |
title_fullStr |
Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing |
title_full_unstemmed |
Prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing |
title_sort |
prospects of laboratory risk evaluation of multiple sclerosis relapse and progressing |
publisher |
Siberian State Medical University (Tomsk) |
series |
Bûlleten' Sibirskoj Mediciny |
issn |
1682-0363 1819-3684 |
publishDate |
2010-08-01 |
description |
The Relapsing-Remitting Multiple Sclerosis (MS) patients research has revealed that the matrix metalloproteinase-2 level in cerebrospinal fluid which is higher then 30 ng/ml during the relapse and/or remission period increases repeated relapse risk during 2 years term by 2.8 times. The rapid MS progressing is associated with the high level of adhesion molecule (sPECAM) in cerebrospinal fluid. |
topic |
multiple sclerosis cerebrospinal fluid |
url |
https://bulletin.tomsk.ru/jour/article/view/1646 |
work_keys_str_mv |
AT ivsmagina prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing AT sayelchaninova prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing AT avpopovtseva prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing AT yunignatova prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing AT aogridina prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing AT asfedyanin prospectsoflaboratoryriskevaluationofmultiplesclerosisrelapseandprogressing |
_version_ |
1721253753286295552 |